Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673329 | 0.92 | FFAR4 (0.61) | FFAR4FFAR1L3MBTL1KMT2AAPP | |
| SCHEMBL3690496 | 0.92 | CALM1 (0.60) | FFAR4FFAR1KMT2AAPPMEN1 | |
| SCHEMBL7995941 | 0.91 | FFAR4 (0.60) | FFAR4FFAR1L3MBTL1KMT2AAPP | |
| SCHEMBL6582446 | 0.90 | FFAR4 (0.71) | FFAR4FFAR1LMNAKMT2AAPP | |
| SCHEMBL27773869 | 0.89 | PPARA (0.50) | GAAKMT2AAPPMEN1ALDH1A1 | |
| SCHEMBL5685599 | 0.89 | FFAR4 (0.46) | FFAR4FFAR1GAAL3MBTL1LMNA | |
| SCHEMBL8984885 | 0.89 | FFAR4 (0.54) | FFAR4FFAR1L3MBTL1LMNA | |
| SCHEMBL3667217 | 0.87 | LMNA (0.65) | FFAR4FFAR1L3MBTL1LMNAHDAC1 | |
| SCHEMBL6583668 | 0.87 | ALOX5 (0.54) | FFAR4FFAR1GAAL3MBTL1LMNA | |
| SCHEMBL21359040 | 0.86 | FFAR4 (0.51) | FFAR4FFAR1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101668742-B | Bridged six-membered ring compounds | ACTELION PHARMACEUTICALS LTD | 2014-04-30 | — | — | CN | disclosed |
| EP-2152670-B1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-12-25 | — | — | EP | disclosed |
| US-8202885-B2 | Bridged six-membered ring compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-06-19 | — | — | US | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-05-27 | — | — | US | disclosed |
| CN-101668742-A | Bridged six-membered ring compounds | ACTELION PHARMACEUTICALS LTD | 2010-03-10 | — | — | CN | disclosed |
| EP-2152670-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008132679-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-06 | — | — | WO | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20050107432-A1 | Sigma receptor binder containing indanone derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | FFAR4 107/4885FFAR1 74/4885GAA 691/4885 |
| US-20050107432-A1 | Sigma receptor binder containing indanone derivative | SIGMAR1, OPRK1, TMEM97 | FFAR4 211/4885FFAR1 74/4885GAA 4761/4885 |
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | CACNA1E, CACNA1B, CACNA1A | FFAR4 3172/4885FFAR1 2731/4885GAA 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.